PT - JOURNAL ARTICLE AU - Hsu, Chen-Yang AU - Lai, Chao-Chih AU - Yen, Amy Ming-Fang AU - Chen, Sam Li-Sheng AU - Chen, Hsiu-Hsi TI - Efficacy of remdesivir in COVID-19 patients with a simulated two-arm controlled study AID - 10.1101/2020.05.02.20088559 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.02.20088559 4099 - http://medrxiv.org/content/early/2020/05/08/2020.05.02.20088559.short 4100 - http://medrxiv.org/content/early/2020/05/08/2020.05.02.20088559.full AB - While the recent study on the compassionate use of remdesivir for COVID-19 patients has shown a 68% clinical improvement7 it is a one-arm study that renders the evaluation of the efficacy in reducing death and the length of stay of hospitalization intractable due to a lacking of the control group. We came up with a two-arm controlled study design to simulate the treated and the untreated (control group) group by applying two respective transition models to the empirical data on dynamics of the disease severity (Figure 2 of the original article7) that are classified into low- (no and low oxygen supplement), medium- (non-invasive ventilator and high oxygen supplement), and high-(ECMO and invasive ventilator) from enrolment until discharge, death or the end of follow-up. By using a simulated two-arm controlled study, the remdesivir treatment group as opposed to the control group led to a statistically significantly 29% (95% CI: 22-35%) reduction of death from COVID-19. The treated group also revealed a 33% (95% CI 28-38%) significantly higher odds of discharge than the control group. The median time to discharge for the treated group (5.5 days, 16.5 days, and 29.5 days for low-, medium-, and high-risk state, respectively) was around half of those of the control arm. Our results with a simulated two-arm controlled study have not only corroborated the efficacy of remdesivir but also made great contribution to designing a further large-scale randomized controlled trial. They have significant implications for reducing transmission probability and infectious time of COVID-19 patients when contacting with susceptible health care workers during hospitalization.Question What is the efficacy of remdesivir in reducing advanced disease state or death from COVID-19 and the length of stay of hospitalization?Findings Remdesivir treatment results in a 33% significantly higher odds of discharge, a 29% significantly lower risk of death, and a 39% significantly lower risk for the combined endpoint of severe status and death. The median time to discharge for the remdesivir treated group was around half of the median time-to-discharge compared with the control arm.Meaning Remdesivir is effective in treating COVID-19 patients in terms of enhancing recovery and accelerating discharge.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAll data and codes are available from author on request.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and codes are available from the author on request.